ArticleScientific reports2018
Induction of alopecia areata in C3H/HeJ mice using polyinosinic-polycytidylic acid (poly[I:C]) and interferon-gamma.
Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 40 citations in OpenAlex.
- Minoxidil Sulfate Regulates JAK/STAT Signalling and Mitochondrial Function in Alopecia Areata.Experimental dermatology · 2026Article
- Immunopathogenesis and Experimental Models of Alopecia Areata: From Mechanistic Insights to Translational Platforms.Clinical reviews in allergy & immunology · 2026Review
- Alopecia Areata and Atopic Dermatitis: Common Mechanisms and Emerging Therapeutics.Journal of inflammation research · 2026Review
- Minoxidil Promotes Hair Growth in a Mouse Model of Telogen Effluvium Induced by Lipopolysaccharide.The Journal of dermatology · 2025Article
- Pyroptosis in Alopecia Areata: Synthesizing Emerging Hypotheses and Charting a Path to New Therapies.Biomedicines · 2025Review
- Systemic Treatment of Moderate to Severe Alopecia Areata in Adults: Updated Australian Expert Consensus Statement.The Australasian journal of dermatology · 2025Article
- Modulating immune responses in alopecia: therapeutic insights and potential targets of antisense oligonucleotides.BMC immunology · 2025Review
- Discovery of Orally Available Prodrugs of Itaconate and Derivatives.Journal of medicinal chemistry · 2025Article
- The Involvement of RIPK1 in Alopecia Areata.International journal of molecular sciences · 2025Article
- Stem cell activity shapes the pleiotropic effects of IFN-γ and TGF-β in autoimmune diseases, infections, and cancer, and drives autoimmune flares and remissions.Frontiers in immunology · 2025Review
- Article
- γδ T Cells Mediate a Requisite Portion of a Wound Healing Response Triggered by Cutaneous Poxvirus Infection.Viruses · 2024Article
- Involvement of DKK1 secreted from adipose-derived stem cells in alopecia areata.Cell proliferation · 2024Article
- Alopecia Areata: Burden of Disease, Approach to Treatment, and Current Unmet Needs.Clinical, cosmetic and investigational dermatology · 2023Review
- Topical SCD-153, a 4-methyl itaconate prodrug, for the treatment of alopecia areata.PNAS nexus · 2023Article
- Ex Vivo Treatment with Allogenic Mesenchymal Stem Cells of a Healthy Donor on Peripheral Blood Mononuclear Cells of Patients with Severe Alopecia Areata: Targeting Dysregulated T Cells and the Acquisition of Immunotolerance.International journal of molecular sciences · 2022Article
- JAM-A facilitates hair follicle regeneration in alopecia areata through functioning as ceRNA to protect VCAN expression in dermal papilla cells.Precision clinical medicine · 2022Article
- The current state of knowledge of the immune ecosystem in alopecia areata.Autoimmunity reviews · 2022Review
- Article
- NLRP3 inflammasome activation contributes to development of alopecia areata in C3H/HeJ mice.Experimental dermatology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
Abstract
Alopecia areata (AA) is a chronic, relapsing hair-loss disorder that is considered to be a T-cell-mediated autoimmune disease. Several animal models for AA have been created to investigate the pathophysiology and screen for effective therapeutic targets. As C3H/HeJ mice develop AA spontaneously in a low frequency, a novel animal model is needed to establish an AA-like condition faster and more conveniently. In this study, we present a novel non-invasive AA rodent model that avoids skin or lymph-node cell transfer. We simply injected C3H/HeJ mice subcutaneously with interferon-gamma (IFNγ) along with polyinosinic:polycytidylic acid (poly[I:C]), a synthetic dsRNA, to initiate innate immunity via inflammasome activation. Approximately 80% of the IFNγ and poly(I:C) co-injected mice showed patchy AA lesions after 8 weeks. None of the mice displayed hair loss in the IFNγ or poly(I:C) solely injection group. Immunohistochemical staining of the AA lesions revealed increased infiltration of CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.